Drugs / CD20-CD19 cCAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04156178 | Aug 2018 → Sep 2020 | B-cell non-Hodgkin lymphoma, lymphoid leukemia | iCell Gene Therapeutics | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD20-CD19 cCAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04156178 ↗ |
| Modality | Cell therapy | “CD20-CD19 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD20 and CD19 CARs” NCT04156178 ↗ |
| Route | Intravenous | “by IV injection” NCT04156178 ↗ |